Upcoming drugs that inhibit viral entry will be a new frontier for antiretroviral therapy.
Murphy
Mary J
MJ
Section of Infectious Diseases, LSU Health Sciences Center, New Orleans, Louisiana, USA.
D002986:Clinical Trials as Topic; D006678:HIV / Q000502:physiology*; D015700:HIV Envelope Protein gp41 / Q000378:metabolism; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects*; D019713:Receptors, CCR5 / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000378:metabolism
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D019713:Receptors, CCR5; D019718:Receptors, CXCR4